VERU Share Price Performance
US$0.37
-0.44 (-53.94%)
88.8% undervalued intrinsic discount
US$3.33
Fair Value
Price US$0.37
AnalystConsensusTarget US$3.33
Fair ValueUS$3.33
Share PriceUS$0.37
88.8% undervalued intrinsic discount
VERU Community Narratives
AN
Fair Value US$3.33 88.8% undervalued intrinsic discount
Enobosarm Phase III And Sabizabulin Tests Will Yield Mixed Prospects
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
Recent VERU News & Updates
No updates
Veru Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 12, 2025
- Earnings per share (EPS)
- -0.21
- Gross Margin
- 34.67%
- Net Profit Margin
- -184.13%
- Debt/Equity Ratio
- 0%
Veru Inc. Competitors
About VERU
- Founded
- 1971
- Employees
- 210
- CEO
- WebsiteView website
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
U.S. Market Performance
- 7 Days: 0.2%
- 3 Months: 12.2%
- 1 Year: 19.9%
- Year to Date: 7.6%
The Consumer Staples sector gained 3.2% while the market remained flat over the last week. As for the longer term, the market has risen 20% in the past 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading